HDFC Pharma And Healthcare Fund Regular-Growth
Mid CapEquity: Sectoral-PharmaVery High Risk
PaisaSmart ratingNot rated yet
Why this rating
This fund is not currently rated by our system. However, we continuously review and update our ratings, so it may be included in the future.
Our score weighs long-term performance, risk and consistency — not just past returns.
Returns
As of 21 Sep 2026
1W
+0.75%
1M
+3.69%
3M
+10.73%
6M
+30.03%
9M
+28.27%
1Y
+25.06%
2Y
+17.54%
Since launch
+30.64%
Portfolio
As of 31 Aug 2026
Market-cap split
Large cap28.69%Mid cap34.11%Small cap37.20%
P/E
49.59
P/B
6.55
Style
Growth
Sector allocation
Healthcare98.42%
Holdings (40)
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Divi's Laboratories Ltd. | 9.54% | ₹315.9 Cr | 3,33,687 |
| Sun Pharmaceutical Industries Ltd. | 8.94% | ₹296.04 Cr | 14,91,549 |
| Torrent Pharmaceuticals Ltd. | 4.08% | ₹135 Cr | 2,66,486 |
| Max Healthcare Institute Ltd. | 4.06% | ₹134.3 Cr | 12,88,696 |
| Lupin Ltd. | 4.04% | ₹133.82 Cr | 6,11,505 |
| Cipla Ltd. | 3.94% | ₹130.36 Cr | 9,25,035 |
| Aster DM Quality Care Ltd. | 3.84% | ₹127.09 Cr | 16,81,027 |
| Neuland Laboratories Ltd. | 3.70% | ₹122.33 Cr | 53,164 |
| Anthem Biosciences Ltd. | 3.48% | ₹115.35 Cr | 12,91,629 |
| Acutaas Chemicals Ltd. | 3.24% | ₹107.15 Cr | 3,39,010 |
Fund details
In brief
To generate long-term capital appreciation Investment predominantly in equity & equity related instruments of Pharma and healthcare companies.
Investment objective
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Exit load
Exit load of 1%, if redeemed within 30 days.
Fund type
Open-ended
Min lumpsum
₹100
Min withdrawal
₹100
Lock-in
None
SIP
Available
SWP
Available
STP
Available
Purchase cut-off
15:00